A clearer reading

Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo-Controlled Crossover Trial

Study preparation, population, findings and limitations with original source links.

Content reviewed 2026-10-25 · Local preview

Back to all research · More in Sleep

Human2026-02-16

Sleep · CBN

Journal of sleep research · PMID 41698831

Randomized placebo-controlled single-night crossover trial

Studied preparation
Defined oral CBN preparations compared with matched placebo.
Population / model
20 adults with physician-diagnosed insomnia disorder.
What was observed
The primary wake-after-sleep-onset outcome was not significantly changed; some secondary measures differed and adverse events were recorded.
Interpretation limit

Single-night arms and a small sample do not establish sustained benefit, broad safety or equivalence to retail sleep products.

Online publication · Source checked 2026-10-25

Sources, registration and terms

Citation and publication date recorded; peer-review/preprint status not separately classified.

PMC full-text link is recorded; current access and reuse rights are not verified here.

Registry state is a dated sponsor report; it does not confirm current recruitment or establish benefit.

CBN / cannabinol · Human study · Registered trial · Primary versus secondary outcome

Package comparison guides; not clinical equivalence

Suggest a source correction

Copy a note and share it with the person who sent this preview. This page does not send or store your note.

Nothing has been sent.